Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 897-910

  Ait Oudhia, Sihem ^a,b   Scherrmann, Jean Michel ^a   Krzyzanski, Wojciech ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIBODY; ERYTHROPOIETIN; IRON; RECOMBINANT PROTEIN; TRANSFERRIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHROBLAST; ERYTHROCYTE COUNT; ERYTHROCYTE LIFESPAN; ERYTHROPOIESIS; EXPERIMENTAL MODEL; IMMUNOGENICITY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOCYTE; STEM CELL; ALGORITHM; ANIMAL; BLOOD; CELL DIFFERENTIATION; COMPUTER PROGRAM; DRUG EFFECTS; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; HALF LIFE TIME; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; RETICULOCYTE COUNT; STATISTICAL MODEL; WISTAR RAT;

ALGORITHMS; ANIMALS; ANTIBODIES; CELL DIFFERENTIATION; ERYTHROCYTE COUNT; ERYTHROCYTES; ERYTHROID PRECURSOR CELLS; ERYTHROPOIETIN; HALF-LIFE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MODELS, STATISTICAL; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RETICULOCYTE COUNT; SOFTWARE; TRANSFERRIN;

EID: 77956257714     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167304     Document Type: Article

References (45)

1. Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, Narhi L, and Elliott S (2009) Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 98:2198-2211.
2. Akahane K, Tojo A, Fukamachi H, Kitamura T, Saito T, Urabe A, and Takaku F (1989) Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions. Exp Hematol 17:177-182. (Pubitemid 19056044)
3. Archer RK, Festing MF, and Riley J (1982) Haematology of conventionally-maintained Lac:P outbred Wistar rats during the 1st year of life. Lab Anim 16:198-200.
4. Bogdanova A, Mihov D, Lutz H, Saam B, Gassmann M, and Vogel J (2007) Enhanced erythro-phagocytosis in polycythemic mice overexpressing erythropoietin. Blood 110:762-769. (Pubitemid 47105415)
5. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, et al. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475. (Pubitemid 34441737)
6. Chapel SH, Veng-Pedersen P, Schmidt RL, and Widness JA (2001) Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 29:425-431.
7. Cheng H and Jusko WJ (1991) Noncompartmental determination of the mean residence time and steady-state volume of distribution during multiple dosing. J Pharm Sci 80:202-204.
8. D'Argenio DA and Schumitzky A (1997) ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software, Biomedical Simulation Resources, Los Angeles, CA.
9. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
10. 3H]DFP) method. Fundam Appl Toxicol 9:271-276.
11. Dormand JR and Prince PJ (1980) A family of embedded Runge-Kutta formulae. J Comp Appl Math 6:19-26.
12. Dornfest BS, Handler ES, and Handler EE (1971) Reticulocyte sequestration in spleens of normal, anaemic and leukaemic rats. Br J Haematol 21:83-94.
13. Egrie J (1990) The cloning and production of recombinant human erythropoietin. Pharmacotherapy 10:3S-8S.
14. Fisher JW and Nakashima J (1992) The role of hypoxia in renal production of erythropoietin. Cancer 70:928-939.
15. Flaharty KK (1990) Clinical pharmacology of recombinant human erythropoietin (r-HuEPO). Pharmacotherapy 10:9S-14S.
16. Gross AW and Lodish HF (2006) Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281:2024-2032.
17. Hazra A, Krzyzanski W, and Jusko WJ (2006) Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn 33:683-717. (Pubitemid 44819258)
18. Hodges VM, Rainey S, Lappin TR, and Maxwell AP (2007) Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 64:139-158.
19. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527.
20. Kientsch-Engel R, Hallermayer K, Dessauer A, and Wieczorek L (1990) New enzyme-linked immunosorbent assay methods for measurement of serum erythropoietin levels and erythropoietin antibodies. Blood Purif 8:255-259.
21. Kojima S, Haruta J, Enomoto A, Fujisawa H, Harada T, and Maita K (1999) Age-related hematological changes in normal F344 rats: during the neonatal period. Exp Anim 48:153-159.
22. Krzyzanski W, Dmochowski J, Matsushima N, and Jusko WJ (2006) Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J Pharmacokinet Pharmacodyn 33:635-655.
23. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, and Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26:295-306.
24. Krzyzanski W, Perez-Ruixo JJ, and Vermeulen A (2008) Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. J Pharmacokinet Pharmacodyn 35:349-377.
25. Lagarias JC, Reed JA, Wright MH, and Wright PE (1998) Convergence properties of the Nelder-Mead simplex method in low dimensions. SIAM J Optim 9:112-147.
26. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
27. Mager DE and Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589-1596.
28. Mager DE, Woo S, and Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16-24.
29. Mide SM, Huygens P, Bozzini CE, and Fernandez Pol JA (2001) Effects of human recombinant erythropoietin on differentiation and distribution of erythroid progenitor cells on murine medullary and splenic erythropoiesis during hypoxia and post-hypoxia. In Vivo 15:125-132.
30. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, and Jusko WJ (2003) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 306:324-331.
31. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, and Jusko WJ (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44:991-1002.
32. Sharma A, Ebling WF, and Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584.
33. Tillmann HC, Kuhn B, Kränzlin B, Sadick M, Gross J, Gretz N, and Pill J (2006) Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 69:60-67.
34. Trial J and Rice L (2004) Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Des 10:183-190.
35. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, and Widness JA (2004) Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 25:149-156.
36. Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, Lacombe C, and Mayeux P (2000) Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 275:18375-18381.
37. Walrafen P, Verdier F, Kadri Z, Chrétien S, Lacombe C, and Mayeux P (2005) Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105:600-608.
38. Wiczling P and Krzyzanski W (2007) Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. Cytometry A 71:460-467.
39. Wiczling P, Lowe P, Pigeolet E, Lüdicke F, Balser S, and Krzyzanski W (2009) Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet 48:817-826.
40. Wintrobe MM (2003) Wintrobe Clinical Hematology, Lippincott Williams & Wilkins, Philadelphia.
41. Wojchowski DM and Caslake L (1989) Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligand. Blood 74:952-958.
42. Woo S and Jusko WJ (2007) Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672-1678.
43. Woo S, Krzyzanski W, Duliege AM, Stead RB, and Jusko WJ (2008) Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol 48:43-52.
44. Woo S, Krzyzanski W, and Jusko WJ (2006) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 319:1297-1306.
45. Woo S, Krzyzanski W, and Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849-868.